CN106729630A - A kind of compound Chinese medicinal preparation and preparation method for preventing and treating newcastle disease - Google Patents
A kind of compound Chinese medicinal preparation and preparation method for preventing and treating newcastle disease Download PDFInfo
- Publication number
- CN106729630A CN106729630A CN201710117770.8A CN201710117770A CN106729630A CN 106729630 A CN106729630 A CN 106729630A CN 201710117770 A CN201710117770 A CN 201710117770A CN 106729630 A CN106729630 A CN 106729630A
- Authority
- CN
- China
- Prior art keywords
- preparation
- chinese medicinal
- compound chinese
- medicinal preparation
- coptis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 208000010359 Newcastle Disease Diseases 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 22
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 22
- 241000605372 Fritillaria Species 0.000 claims abstract description 17
- 241000241413 Propolis Species 0.000 claims abstract description 17
- 229940069949 propolis Drugs 0.000 claims abstract description 17
- 239000001726 jatropha manihot extract Substances 0.000 claims abstract description 16
- 229940106668 yucca extract Drugs 0.000 claims abstract description 16
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 15
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 15
- 239000011720 vitamin B Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 241000050051 Chelone glabra Species 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 239000000341 volatile oil Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 21
- 241000207929 Scutellaria Species 0.000 description 15
- 241000287828 Gallus gallus Species 0.000 description 14
- 235000013330 chicken meat Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 9
- 244000144977 poultry Species 0.000 description 9
- 235000013594 poultry meat Nutrition 0.000 description 9
- 241000193830 Bacillus <bacterium> Species 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000034994 death Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007661 gastrointestinal function Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229940007046 shigella dysenteriae Drugs 0.000 description 2
- 235000015096 spirit Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 210000000051 wattle Anatomy 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical class C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001653 FEMA 3120 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000921313 Phyllopodium Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- LCXREBMNASQAOC-UHFFFAOYSA-N Worenine Chemical compound C1=C2C(C)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=CC2=C1OCO2 LCXREBMNASQAOC-UHFFFAOYSA-N 0.000 description 1
- 241001532059 Yucca Species 0.000 description 1
- 235000004552 Yucca aloifolia Nutrition 0.000 description 1
- 235000012044 Yucca brevifolia Nutrition 0.000 description 1
- 235000017049 Yucca glauca Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000884 anti-protozoa Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005321 cobalt glass Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055705 pangamic acid Drugs 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229930193981 timosaponin Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of compound Chinese medicinal preparation that can prevent and treat ewcastle disease, the compound Chinese medicinal preparation is prepared from by the bulk drug of following weight proportion：The 200g of the coptis 50, the 300g of the root of large-flowered skullcap 75, the 300g of folium isatidis 75, the 400g of the wind-weed 100, the 400g of fritillaria 100, the 200g of propolis 25, the 200g of yucca extract 25,400mg, the EGF 1 × 10 of vitamin B 1006‑4×106IU。
Description
Technical field
The invention belongs to veterinary Chinese medicine technical field, and in particular to a kind of compound Chinese medicinal preparation of preventing and treating ewcastle disease and preparation
Method.
Background technology
Ewcastle disease is also referred to as philippine fowl disease, is the chicken and the acute highly contagious disease of various birds caused by virus,
The death rate is high, serious to poultry husbandry harm, has a strong impact on poultry cultivation benefit.Ewcastle disease is in often acute sepsis shape, main special
Levy is expiratory dyspnea, just dilute, neurological disorders, mucous membrane and serous coat bleeding.There are velogen strain and the class of low virulent strain two.Virus is divided into low toxicity power
Type (i.e. delayed type), medium virulence type (i.e. middle hair style), strong virus force type (i.e. anaphylactic type) 3 types, most high intensity virulent strains often belong to
Thermophilic visceratonia NDV.Chicken section animal can all suffer from this disease, and family chicken is most susceptible, and chick is higher than Adult Chicken neurological susceptibility.It is acute
Diseased chicken body temperature up to 44 DEG C, in lethargic sleep shape, be preced with and wattle be in kermesinus or black purple by down in spirits, loose random when type is fallen ill,
Crop is spoken in a low voice interior often hydraulically full and gas, expiratory dyspnea, and throat sends cackle, and excrement is thin, stench, general death in 2~5 days.
Subacute or chronic type symptom is similar to acute, but the state of an illness is lighter, nervous symptoms, leg, wings are benumbed, ataxia, head occurs
Bent to layback or to one side etc., the course of disease is most final dead up to 1~2 month.To reduce the incidence of ewcastle disease, improve
Culture benefit, should with improve poultry immunity, alleviate stress, clearing heat and detoxicating, clear purte the white, clearing lung and eliminating the phlegm, cool blood eliminating dampness, adjustment
Gastrointestinal function, antidysentery with astringent, trophic nerve are principle.
The present invention is directed to the Chinese medicine compound prescription that the birds exploitation of ewcastle disease easily occurs according to instruction of Chinese Medicine theory, according to immunity
Lowly, easily there is stress reaction, ewcastle disease easily occurs, the clinical conditions such as respiratory symptom, symptom of digestive tract, nervous symptoms occur
Wait, from " improve poultry immunity, alleviate stress, clearing heat and detoxicating, clear purte the white, clearing lung and eliminating the phlegm, cool blood eliminating dampness, adjust stomach and intestine work(
The aspects such as energy, antidysentery with astringent, trophic nerve " are set about, and develop a kind of determined curative effect, safe ready, Small side effects, price low
The compound Chinese medicinal preparation of honest and clean preventing and treating ewcastle disease, can effectively prevent and treat ewcastle disease, be also avoided that and excessively use chemicals, antibiosis
The medicament residue that element is caused.
The content of the invention
It is an object of the invention to be to cause serious harm to poultry cultivation industry for ewcastle disease, the death rate is high, serious shadow
Rung the practical problem of culture benefit etc., there is provided one kind can be improved during large-scale cultivation birds poultry immunity,
Alleviate stress, clearing heat and detoxicating, clear purte the white, clearing lung and eliminating the phlegm, cool blood eliminating dampness, adjustment gastrointestinal function, antidysentery with astringent, trophic nerve
Compound Chinese medicinal preparation.
The technical scheme that uses to achieve the above object of the present invention is：A kind of compound Chinese medicinal preparation for preventing and treating ewcastle disease, institute
Compound Chinese medicinal preparation is stated to be prepared from by following bulk drug：The coptis, the root of large-flowered skullcap, folium isatidis, the wind-weed, fritillaria, propolis, yucca are extracted
Thing, vitamin B, EGF.
Further, the compound Chinese medicinal preparation is prepared from by the bulk drug of following weight proportion：Coptis 50-200g,
Root of large-flowered skullcap 75-300g, folium isatidis 75-300g, wind-weed 100-400g, fritillaria 100-400g, propolis 25-200g, yucca extract 25-
200g, vitaminB10 0-400mg, EGF 1 × 106-4×106IU。
Preferably, the compound Chinese medicinal preparation is prepared from by the bulk drug of following weight proportion：Coptis 75-125g, Huang
A kind of reed mentioned in ancient books 100-200g, folium isatidis 100-200g, wind-weed 150-300g, fritillaria 150-300g, propolis 50-150g, yucca extract 50-
150g, pangamic acid 0-300mg, EGF 1.5 × 106-2.5×106IU。
Most preferably, the compound Chinese medicinal preparation is prepared from by the bulk drug of following weight proportion：Coptis 100g, the root of large-flowered skullcap
150g, folium isatidis 150g, wind-weed 200g, fritillaria 200g, propolis 120g, yucca extract 150g, vitamin B 200mg, EGF 2
×106IU。
Compound Chinese medicinal preparation of the present invention is traditional Chinese powder medicine, capsule, oral liquid formulation, granule formulation or parenteral solution
Formulation.Preparation determines usage and dosage according to condition when in use, can take 1-2 times daily, and per kilogram of body weight 0.5-5g agent is pressed every time
Amount.
The invention also discloses the Chinese medicine compound prescription preparation method of above-mentioned preventing and treating ewcastle disease, comprise the following steps that：
The first step, takes the coptis, the root of large-flowered skullcap, folium isatidis, the wind-weed, fritillaria add weight for 6-10 times is measured water immersion 0.5-3 hours, carries
Take volatile oil 6-10 hours, collect volatile oil, volatile oil is with beta-schardinger dextrin by weight 1:10 inclusions, 35-50 DEG C of drying is carried
Liquid after taking, another device storage；
Second step, by the first step to the dregs of a decoction measure decocting with 8-15 times of propolis, yucca extract plus mixture weight
Boil 3-5 times, 2 hours every time, merge decoction liquor, filtering merges with the liquid that the first step is obtained, stands overnight, leaching supernatant,
It is concentrated under reduced pressure into relative density 1.21~1.27 (50 DEG C), is dried to dry cream；
3rd step, dry cream is ground into fine powder with volatile oil beta cyclodextrin inclusion complex, crosses 100 mesh sieves, adds vitamin B, EGF
And dextrin, mix, prepare oral liquid formulation, capsule formulation, granule formulation or parenteral solution formulation；
Further, the coptis, the root of large-flowered skullcap, folium isatidis, the wind-weed, fritillaria add 8 times of amount water to soak 0.5 hour in the first step；
Further, drying temperature is 40 DEG C in the first step；
Further amount of water is 10 times of amount water in second step；
Further, it is 3 times that number of times is decocted in second.
The coptis：Category Ranunculaceae, Coptis herbaceos perennial, phyllopodium are hesitated, hard papery, ovate triangle, and three totally cleave, in
There is sharp sawtooth at centre sliver ovate rhombus, pinniform drastic crack, edge, and life sliver in side does not wait 2 drastic cracks；Petiole 5-12cm long.Containing many in stem
Plant isoquinoline alkaloid, content of berberine highest, and coptisine, worenine, jateorrhizine etc..The coptis has very strong
Antibacterial action, suppresses staphylococcus aureus, hemolytic streptococcus, pneumococcus, diplococcus meningitidis, shigella dysenteriae, anthrax
Bacillus etc..Also have antiviral, antiprotozoan effect.In addition the coptis also has detoxication, such as confrontation bacteriotoxin, reduces golden yellow Portugal
Grape coccus coagulase, hemolysin potency, reduce virulence of Escherichia coli etc..And anti-inflammatory, antipyretic effect.
The root of large-flowered skullcap：It is lamiaceae labiatae scutellaria herbaceos perennial.The root of the root of large-flowered skullcap is used as medicine, bitter, cold in nature, have heat-clearing and damp-drying drug,
Purging intense heat and detonicating, hemostasis, it is antiabortive the effects such as.The root of large-flowered skullcap has antibacterial, antiviral work containing various flavone components such as baicalin, baicaleins
With to alpha streptococcus, Diplococcus pneumopniae, diplococcus meningitidis, staphylococcus aureus, corynebacterium diphtheriae, tubercle bacillus, dysentery
Various coccuses such as bacillus and comma bacillus and bacillus and influenza virus have inhibitory action.In addition with anti-inflammatory, suppress immune
The effect such as reaction.
Folium isatidis：Folium isatidis contains indigo, and the in vitro test of smalt leaf decoction is to staphylococcus aureus, alpha streptococcus, brain
Film inflammation diplococcus, streptococcus pneumonia, micrococcus catarrhalis, typhoid bacillus, Escherichia coli, Bacillus influenzae, corynebacterium diphtheriae and shigella dysenteriae
There is certain inhibitory action；Folium isatidis also has inhibitory action big in addition japanese encephalitis virus, mumps virus, influenza virus etc.
Leafiness has killing Leptospira and anti-endotoxin effect.
The wind-weed：Control dysphoria with smothery sensation to quench one's thirst, cough with lung heat.For cough with lung heat or deficiency of Yin cough caused by dryness, the phlegm card such as thick.Have containing timosaponin
Clear purte the white, the effect of nourishing Yin and moistening lung.Effect with resisting pathogenic microbes, to staphylococcus, typhoid bacillus, Pasteurella, pair
Typhoid bacillus, Escherichia coli etc. have different degrees of inhibitory action.Additionally, with antipyretic and regulation cortin effect.
Fritillaria：It is relatively strong with relieving cough and reducing sputum effect, and have functions that clearing heat and detoxicating and moistening lung, abundant expectoration phlegm can be used less,
It is particularly well-suited to the cough caused by the dryness of the lung or autumn-dryness disease.Cough, mouth and nose drying, dry throat and mouth etc. can be alleviated, in addition with certain
Effect and anti-inflammatory of purging intense heat, antiviral and antineoplastic action.
Propolis：Energy sterilizing, sterilized, sterilization, antibacterial, antiviral, mould proof, anti-corrosion, solve antibiotic only to single micro- life
The defect that thing works, and side effect is minimum.The common fungi of propolis, tinea bacterium etc. have inhibitory action；To herpesviral, influenza
Virus etc. has preferable killing action；There is neutralization to exotoxins such as Escherichia coli, salmonellas；Meanwhile, it is anti-with some
Rhzomorph is shared, and can be improved antibacterial activity and be extended its effect.It is also natural polyphenoils.Additionally, propolis also has can increase
Various effects such as strong immunity, promotion cytothesis effect, easing pain and diminishing inflammation.
Yucca extract：Main active is polysaccharide, saponin and polyphenol.Cud infusorian and gram sun can be suppressed
Property bacteria growing and breeding, improve gram-negative bacteria ratio and activity, reduce albumen rumen digestibility.Yucca extract contains very strong
Suction-operated, its concentration can be reduced directly in conjunction with pernicious gases such as ammonia, hydrogen sulfide and methyl indols, and can promote to raise
Material is decomposed, and improves digestibility, and favourable nutritional ingredient absorbs, and suppresses the decomposition of urea.Additionally, yucca extract can promote animal
Grow up, improve animal product quality, promote the effects such as nutrition digestion absorption.
Vitamin B：Vitamin B mainly has vitamin B1, vitamin B2, vitamin B3, a vitamin B6, pantothenic acid, biotin,
Folic acid, vitamin B12, all of vitamin B must play a role simultaneously, referred to as the fusion of VB.Wherein vitamin B1 is made
For the coenzyme of many enzymes plays the role of important to the glycometabolism of human normal, it may also suppress the activity of cholinesterase, and choline
Esterase is a kind of important neurotransmitter, thus produces influence to nerve conduction；Vitamin B2 passing in biological oxidation process
Oxygen is acted on, the substance metabolism process in regulation human body；Vitamin B6 can also participate in various amino acid as the coenzyme of various enzymes
Metabolism, promote amino acid absorption and protein synthesis, be material necessary to cell growth, it can also promote fat
Metabolism, participates in the synthesis of neurotransmitter, the synthesis of hemoglobin and produces influence to normal reproductive function.
EGF:That is epithelical cell growth factor, also known as oligopeptides -1, is a kind of active material in human body, by 53 amino groups
Into active peptides, by stimulate EGFR tyrosine phosphorylation, reach repairing hyperplasia cells of superficial layer,
Its maximum feature is the Proliferation, Differentiation that can promote cell, so as to replace the cell of aging and death with newborn cell.EGF has
There are acceleration skin and mucous membrane wound healing, anti-inflammatory analgesic, prevent effect of ulcer.
In sum, by adopting the above-described technical solution, the beneficial effects of the invention are as follows：
Ewcastle disease, raising bird immunity can be prevented and treated during large-scale cultivation poultry using this kind of compound Chinese medicinal preparation
Power, reduces ewcastle disease occurrence probability.The compound Chinese medicinal preparation have improve poultry immunity, alleviate stress, it is clearing heat and detoxicating, rush down clearly
Lung-fire, clearing lung and eliminating the phlegm, cool blood eliminating dampness, adjustment gastrointestinal function, antidysentery with astringent, the function of trophic nerve, and can avoid because excessively making
The medicament residue caused with chemicals, antibiotic, in can be widely applied to the practice of ewcastle disease.
Specific embodiment
The technical scheme in the embodiment of the present invention is clearly and completely described below.Based on the implementation in the present invention
Example, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made is belonged to
The scope of protection of the invention.
Embodiment 1
A kind of Herbal compound capsule agent for preventing and treating ewcastle disease, including：Coptis 75-125g, root of large-flowered skullcap 100-200g, folium isatidis
100-200g, wind-weed 150-300g, fritillaria 150-300g, propolis 50-150g, yucca extract 50-150g, vitamin B 150-
300mg、EGF 1.5×106-2.5×106IU。
Its specific preparation method is as follows：
The first step, takes the coptis, the root of large-flowered skullcap, folium isatidis, the wind-weed, fritillaria add weight for 8 times of amount water soak 0.5 hour, and extraction is waved
Hair oil 8 hours, collects volatile oil, and volatile oil is with beta-schardinger dextrin by weight 1:10 inclusions, 40 DEG C of dryings, the liquid after extraction,
Another device storage；
Second step, by the first step to the dregs of a decoction boil 3 with 10 times of amounts decocting of propolis, yucca extract plus mixture weight
It is secondary, 2 hours every time, merge decoction liquor, filtering merges with the liquid that the first step is obtained, stands overnight, leaching supernatant, depressurizes
It is concentrated into relative density 1.21~1.27 (50 DEG C), is dried to dry cream；
3rd step, dry cream is ground into fine powder with volatile oil beta cyclodextrin inclusion complex, crosses 100 mesh sieves, adds vitamin B, EGF
And dextrin, mix, then carry out causing grain to process and dry, obtain compound particles, then to adding stearic acid in compound particles
Magnesium, the magnesium stearate and the compound particles mass ratio are 0.25:0.5, capsule 's content is obtained, by described capsule
Content obtains final product capsule in being fitted into capsule housing.
Embodiment 2
A kind of complex injection of Chinese materia medica for preventing and treating ewcastle disease, including：Coptis 75-125g, root of large-flowered skullcap 100-200g, folium isatidis
100-200g, wind-weed 150-300g, fritillaria 150-300g, propolis 50-150g, yucca extract 50-150g, vitamin B 150-
300mg、EGF 1.5×106-2.5×106IU。
Its specific preparation method is as follows：
The first step, takes the coptis, the root of large-flowered skullcap, folium isatidis, the wind-weed, fritillaria add weight for 8 times of amount water soak 0.5 hour, and extraction is waved
Hair oil 8 hours, collects volatile oil, and volatile oil is with beta-schardinger dextrin by weight 1:10 inclusions, 40 DEG C of dryings, the liquid after extraction,
Another device storage；
Second step, by the first step to the dregs of a decoction boil 3 with 10 times of amounts decocting of propolis, yucca extract plus mixture weight
It is secondary, 2 hours every time, merge decoction liquor, filtering merges with the liquid that the first step is obtained, stands overnight, leaching supernatant, depressurizes
It is concentrated into relative density 1.21~1.27 (50 DEG C), is dried to dry cream；
3rd step, dry cream is ground into fine powder with volatile oil beta cyclodextrin inclusion complex, crosses 100 mesh sieves, adds vitamin B, EGF
And dextrin, mix, the powder of acquisition is added into the sodium chloride and appropriate water for injection relative to 2 times of its quality, enter one after dissolving again
Step injects water to the volume of needs, and filtering, embedding, sterilizing obtains the parenteral solution for needing.
Embodiment 3
1st, long term toxicity test process
Experimental agents are set as using Wistar rats (Beijing Vital River Experimental Animals Technology Co., Ltd.'s offer)
Capsule 8g/kg, 4g/kg, 2g/kg of high, medium and low three dosage, respectively embodiment 1 formula.A control group separately is set, continuously
After gastric infusion 90 days, 180 days and Some Animals are discontinued 10 days, observation is to rat items physiology, the influence of biochemical indicator.Experiment
Result shows：With various dose to rat continuous oral 180 days, on the food-intake and body weight increase of rat without influence.To liver
Renal function does not find that overt toxicity is acted on.Blood routine, blood biochemistry, urine biochemistry and marrow piece etc. are showed no and are significantly affected,
Compare no significant difference with control group between each group.
2nd, acute toxicity test process：
Using ICR mouse (Beijing Vital River Experimental Animals Technology Co., Ltd.'s offer) 40, body weight at 25-30 grams,
Carry out acute toxicity testing.Mouse is randomly divided into two groups, i.e. control group, administration group, fasting 12 hours before experiment, then give as
Chinese medicine capsules suspension of the invention (capsule is dissolved in water acquisition suspension) gavage that embodiment 1 is prepared,
To the median lethal dose (LD being administered50) experiment measure has been carried out, but do not measure LD50, therefore carried out mtd test.
As a result：With Cmax (60%), maximum dosage-feeding (120ml/kg, part gives for four times in a day) 100g/kg gavages, equivalent to
Crude drug amount 60g/kg, in seven days mouse none is dead, put to death each internal organs of mouse anatomic observation and do not find toxic reaction, administration group with
Control group mice is without any difference.
3rd, ewcastle disease pharmacodynamics test
Experimental animal：3 week old male SPF Leghorns 60, it is immune without newcastle disease vaccine.Stochastic averagina be divided into 3 groups it is (right
According to group, model group, Chinese medicine group (embodiment of the present invention 1)), every group of 20 chickens.Therapeutic test starts preceding adaptability and raises 1 week.Raise
Feed chicken feed (being free of any medicated premix), free choice feeding and drinking-water, isolated plane cage, control group isolated rearing.Mould
Type group, Chinese medicine group test chicken intramuscular injection Virulent Newcastle Disease Virus (dilute 10 before use6Use again), 24h starts administration and controls after infection
Treat, control group, medicine group group of the present invention each take capsule 1, daily 2 times, successive administration 7d.After attacking malicious 24h, test chicken
100% morbidity.Clinical manifestation is：Down in spirits, loose random, in lethargic sleep shape, hat and wattle are in kermesinus or black purple, breathing
Difficulty, throat sends cackle, and excrement is thin, stench, nervous symptoms occurs.During testing, medicine group medication of the present invention is controlled
After treating 7 days, healing number of elements 12, invalid number of elements 0, cure rate is 60%.Spirit, appetite, breathing and mucous membrane after diseased chicken treatment
Color recovers normal, feather smooth-going, and excrement recovers normal, and only a small number of diseased chickens still occasionally arrange loose stool.
Cut open inspection visible part model group chicken has mucous membrane and a serous coat bleeding, lymphoid tissue swelling, bleeding and necrosis, and bleeding is especially
It is obvious with alimentary canal and respiratory tract.Wash and gas of the crop full of acid smell.Glandular stomach myxedema, its nipple and breast
There is the blutpunkte of distinctness between head, muscular stomach cuticula has blutpunkte, and small intestine to caecum and rectum have blutpunkte, tracheorrhagia, surrounding
Tissue edema, heart hat fat has tiny blutpunkte.
Additionally, from the point of view of production performance, daily gain and the feed intake of model group chicken are significantly reduced, the production of Chinese medicine group chicken
Though performance has decline compared with control group, but still is significantly higher than model group.
The therapeutic effect statistical form of table 1
Influence of the table 2 to performance of poultry
Result of the test shows that middle medicine composite preparation group has good curative effect in terms of ewcastle disease is treated.
The present invention is found surprisingly that the present invention has synergistic function, and to prove the effect, the present invention has carried out following
Experiment：
Remove the coptis, the root of large-flowered skullcap in embodiment 1, other compositions are constant, carry out the pharmacodynamics test in above-described embodiment 3, tie
Fruit discovery, removes the decline 25% more of the invention of the coptis, root of large-flowered skullcap group cure rate.
Remove that folium isatidis, the wind-weed, other compositions are constant in embodiment 1, carry out the pharmacodynamics test in above-described embodiment 3,
Result discovery, removes the decline 17% more of the invention of folium isatidis, wind-weed group cure rate.
The therapeutic effect of table 3 compares
The therapeutic effect of table 4 compares
Above-described embodiment simply to illustrate that technology design of the invention and feature, the purpose is to be to allow in the art
Those of ordinary skill will appreciate that present disclosure and implement according to this that it is not intended to limit the scope of the present invention.It is all
It is the equivalent change or modification according to done by the essence of present invention, should all covers within the scope of the present invention.
Claims (9)
1. it is a kind of prevent and treat ewcastle disease compound Chinese medicinal preparation, it is characterised in that the compound Chinese medicinal preparation is by following weight proportion
Bulk drug be prepared from：Coptis 50-200g, root of large-flowered skullcap 75-300g, folium isatidis 75-300g, wind-weed 100-400g, fritillaria 100-
400g, propolis 25-200g, yucca extract 25-200g, vitamin B 100-400mg, EGF 1 × 106-4 × 106IU.
2. compound Chinese medicinal preparation as claimed in claim 1, it is characterised in that the compound Chinese medicinal preparation is by following weight proportion
Bulk drug be prepared from：Coptis 75-125g, root of large-flowered skullcap 100-200g, folium isatidis 100-200g, wind-weed 150-300g, fritillaria
150-300g, propolis 50-150g, yucca extract 50-150g, vitamin B 150-300mg, EGF 1.5 × 106-2.5×
106IU。
3. compound Chinese medicinal preparation as claimed in claim 2, it is characterised in that the compound Chinese medicinal preparation is by following weight proportion
Bulk drug be prepared from：Coptis 100g, root of large-flowered skullcap 150g, folium isatidis 150g, wind-weed 200g, fritillaria 200g, propolis 120g, yucca
Extract 150g, vitamin B 200mg, EGF 2 × 106IU。
4. compound Chinese medicinal preparation as claimed in claim 1, it is characterised in that the compound Chinese medicinal preparation is traditional Chinese powder medicine, glue
Wafer, oral liquid formulation, granule formulation or parenteral solution formulation.
5. the preparation method of the compound Chinese medicinal preparation described in claim 1, it is characterised in that the preparation method specific steps are such as
Under：
The first step, takes the coptis, the root of large-flowered skullcap, folium isatidis, the wind-weed, fritillaria add weight for 8 times of amount water soak 0.5 hour, extracts volatile oil 8
Hour, volatile oil is collected, volatile oil is with beta-schardinger dextrin by weight 1:10 inclusions, 40 DEG C of dryings, the liquid after extraction, another device
Storage；
Second step, by the first step to the dregs of a decoction boiled 3 times with 10 times of amounts decocting of propolis, yucca extract plus mixture weight,
2 hours every time, merge decoction liquor, filtering merges with the liquid that the first step is obtained, stands overnight, leaching supernatant, concentrated under reduced pressure
To relative density 1.21~1.27 (50 DEG C), it is dried to dry cream；
3rd step, dry cream is ground into fine powder with volatile oil beta cyclodextrin inclusion complex, crosses 100 mesh sieves, adds vitamin B, EGF and paste
Essence, mixes, and then carries out causing grain to process and dry, and obtains compound particles, then to adding magnesium stearate, institute in compound particles
It is 0.25 to state magnesium stearate and the compound particles mass ratio:0.5, capsule 's content is obtained, by described capsule contents
Thing obtains final product capsule in being fitted into capsule housing.
6. preparation method as claimed in claim 5, it is characterised in that the coptis, the root of large-flowered skullcap, folium isatidis, the wind-weed, fritillaria in the first step
Plus 8 times of amount water soak 0.5 hour.
7. preparation method as claimed in claim 5, it is characterised in that drying temperature is 40 DEG C in the first step.
8. preparation method as claimed in claim 5, it is characterised in that amount of water is 10 times of amount water in second step.
9. preparation method as claimed in claim 5, it is characterised in that it is 3 times that number of times is decocted in second step.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710117770.8A CN106729630A (en) | 2017-03-01 | 2017-03-01 | A kind of compound Chinese medicinal preparation and preparation method for preventing and treating newcastle disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710117770.8A CN106729630A (en) | 2017-03-01 | 2017-03-01 | A kind of compound Chinese medicinal preparation and preparation method for preventing and treating newcastle disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106729630A true CN106729630A (en) | 2017-05-31 |
Family
ID=58959146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710117770.8A Pending CN106729630A (en) | 2017-03-01 | 2017-03-01 | A kind of compound Chinese medicinal preparation and preparation method for preventing and treating newcastle disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106729630A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755505A (en) * | 2012-07-11 | 2012-10-31 | 山东省农业科学院家禽研究所 | Chinese medicinal herb mixture for preventing and treating new castle disease and production technology |
| CN105497879A (en) * | 2015-12-31 | 2016-04-20 | 中悦民安（北京）科技发展有限公司 | Anti-stress traditional Chinese medicine compound capable of improving product flavor |
| CN105999231A (en) * | 2016-06-06 | 2016-10-12 | 张英杰 | Polypeptide composition, composition for improving livestock and poultry immune function, and preparation method of composition for improving livestock and poultry immune function |
-
2017
- 2017-03-01 CN CN201710117770.8A patent/CN106729630A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755505A (en) * | 2012-07-11 | 2012-10-31 | 山东省农业科学院家禽研究所 | Chinese medicinal herb mixture for preventing and treating new castle disease and production technology |
| CN105497879A (en) * | 2015-12-31 | 2016-04-20 | 中悦民安（北京）科技发展有限公司 | Anti-stress traditional Chinese medicine compound capable of improving product flavor |
| CN105999231A (en) * | 2016-06-06 | 2016-10-12 | 张英杰 | Polypeptide composition, composition for improving livestock and poultry immune function, and preparation method of composition for improving livestock and poultry immune function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101869220B (en) | Traditional herbal medicine feed addictive for preventing and controlling swine high fever syndrome | |
| CN101698024B (en) | Traditional Chinese medicine for treating respiratory diseases and promoting growth for swine and preparation method thereof | |
| CN101836691B (en) | Chinese medicinal herb feed additive | |
| CN103238756A (en) | Compound feed for finishing pigs and preparation method thereof | |
| WO2020155318A1 (en) | Traditional chinese medicine preparation for treatment of bacterial respiratory tract disease in livestock and production technique thereof | |
| CN102058810B (en) | Lung-clearing asthma-relieving phlegm-reducing Chinese patent drug | |
| CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
| CN104644757A (en) | Traditional Chinese medicine oral liquid for treating avian influenza and preparation method thereof | |
| CN104222522A (en) | Chicken feed capable of preventing pullorum of black-bone chicken and preparation method of chicken feed | |
| CN106511675A (en) | Medicine for preventing and treating poultry diseases and preparation method of medicine | |
| CN106615969A (en) | Traditional Chinese medicine feed for preventing and treating avian salmonellosis and preparation method of traditional Chinese medicine feed | |
| CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
| CN111588801B (en) | Traditional Chinese medicine dispersible granule for preventing livestock and poultry epidemic diseases and preparation method thereof | |
| CN104147586A (en) | Chinese herbal medicine composition and fodder for preventing and treating cold irritable enteritis of quails | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN106729630A (en) | A kind of compound Chinese medicinal preparation and preparation method for preventing and treating newcastle disease | |
| CN102885927A (en) | Traditional Chinese medicine composition for treating pullorum disease and preparation method thereof | |
| CN105192430A (en) | Chicken feed additive for preventing chicken diseases | |
| CN111603514A (en) | Veterinary anti-mycoplasma infection traditional Chinese medicine compound preparation and preparation method and application thereof | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN101376006A (en) | Chinese medicine oral liquid with heat-clearing and detoxicating, cough-suppressing and asthma-relieving functions as well as application thereof for livestock and poultry | |
| CN101085048B (en) | Traditional Chinese medicine for detoxicating for animals and preparation method thereof | |
| CN104324301A (en) | Anti-coccidiosis traditional Chinese medicine extract | |
| CN110338285A (en) | A kind of mongolian veterinary drug feed addictive and preparation method and application for preventing and treating pneumonia of sheep | |
| CN104324302A (en) | Preparation method of anti-coccidiosis traditional Chinese medicine extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |